<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001989</url>
  </required_header>
  <id_info>
    <org_study_id>106A</org_study_id>
    <nct_id>NCT00001989</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin</brief_title>
  <official_title>A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genelabs Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      This study involves GLQ223 administration to patients who have not previously been exposed to&#xD;
      it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will&#xD;
      include survival, opportunistic infections, T4 cell count, and assessments of viral load.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve the randomization of patients with 200-500 T4 cells and AIDS or ARC to&#xD;
      one of three treatment arms: zidovudine alone, GLQ223 alone, or GLQ223 plus zidovudine.&#xD;
      Patients randomized to receive GLQ223 will receive an infusion every three weeks for 45&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trichosanthin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine, trimethoprim/sulfamethoxazole, or dapsone for PCP&#xD;
             prophylaxis.&#xD;
&#xD;
          -  Chronic suppressive therapy for the following infections:&#xD;
&#xD;
        Toxoplasmosis (pyrimethamine, sulfadiazine, or clindamycin). Cryptococcosis (fluconazole).&#xD;
        Candidiasis (ketoconazole). Herpes simplex virus (acyclovir). Mycobacterium avium&#xD;
        (isoniazid, clofazimine, amikacin, rifampin, rifabutin, ethambutol, or other drug with&#xD;
        written permission of the sponsor).&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Patients whose CD4+ count falls below 200 at two consecutive measurements must receive&#xD;
             prophylaxis for PCP and any other clinically indicated conditions.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  An active AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Evidence of AIDS dementia complex or active neurologic disease, including progressive&#xD;
             multi-focal leukoencephalopathy (PML), poorly controlled seizure disorder or active&#xD;
             CNS infection.&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion is sufficient to prevent adequate&#xD;
             compliance with the study.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Therapeutic agents specific for HIV disease that have not received FDA approval.&#xD;
&#xD;
          -  Biologic response modifiers, including interferon, interleukin-2 (IL-2), and leukocyte&#xD;
             stimulating hormones (GM-CSF, G-CSF).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  An active AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Evidence of AIDS dementia complex or active neurologic disease, including progressive&#xD;
             multi-focal leukoencephalopathy (PML), poorly controlled seizure disorder or active&#xD;
             CNS infection.&#xD;
&#xD;
          -  Participation in other clinical studies, including investigational therapy of HIV&#xD;
             infection.&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion is sufficient to prevent adequate&#xD;
             compliance with the study.&#xD;
&#xD;
          -  History of prior use of GLQ223 or trichosanthin or presence of anti-GLQ223 serum IgG&#xD;
             antibody as measured by Western blot.&#xD;
&#xD;
          -  Inability to provide written informed consent.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  History of prior use of GLQ223 or trichosanthin or presence of anti-GLQ serum IgG&#xD;
             antibody as measured by Western blot.&#xD;
&#xD;
        Excluded within 30 days prior to enrollment:&#xD;
&#xD;
          -  Use of unapproved therapeutic agents specific for HIV disease, including ddC.&#xD;
&#xD;
          -  Use of biologic response modifiers, including interferon, interleukin-2, and leukocyte&#xD;
             stimulating hormones (GM-CSF, G-CSF).&#xD;
&#xD;
        Patients have the following:&#xD;
&#xD;
          -  HIV positive by ELISA with confirmation by Western blot.&#xD;
&#xD;
          -  Symptomatic with AIDS-Related Complex or AIDS by CDC classification.&#xD;
&#xD;
          -  History of zidovudine therapy at a dose equal to or more than 300 mg daily for at&#xD;
             least 9 consecutive months immediately prior to entry into study.&#xD;
&#xD;
          -  CD4 count equal to or more than 200 and equal to or less than 500 (mean of 2 readings&#xD;
             one week apart).&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Zidovudine therapy at a dose equal to or more than 300 mg daily for at least 9 months&#xD;
             immediately prior to entry into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Larry A Waites</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Mem Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Veterans Administration Med Ctr</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Institute Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp and Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Byers VS, Levin AS, Malvino A, Waites L, Robins RA, Baldwin RW. A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res Hum Retroviruses. 1994 Apr;10(4):413-20. doi: 10.1089/aid.1994.10.413.</citation>
    <PMID>7915124</PMID>
  </reference>
  <reference>
    <citation>Waites AL, Klimas N, Yangco B, Chew T, Lang W, Von Roenn J, Torres G, Gorelick KJ, Kahn JO. Final report of a randomized phase II study of GLQ223 in AIDS and ARC. Program Abstr Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7:61</citation>
  </reference>
  <verification_date>October 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trichosanthin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Trichosanthin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

